In today’s ACT Brief, we hear how sponsors may redefine efficiency to protect patient access in 2026, review Verana Health’s ...

Unpack how rising competition for the same high-profile sites is slowing startup and enrollment—and what sponsors must change ...

Real-world adverse events are rarely monocausal. They emerge from the interaction of drug exposure, comorbid conditions, physiological states, concomitant medications, and patient-specific ...

Explore how sponsors can recalibrate efficiency efforts to avoid overconcentrating trials at familiar sites and instead ...

In today’s ACT Brief, we examine the growing challenges of sourcing comparator drugs across the EU, highlight a new AI-driven ...

In today’s ACT Brief, we examine why representative enrollment remains a barrier in US cancer trials, review Johnson & ...

The merger enhances Verana Health's data capabilities across oncology, ophthalmology, urology, and neurology, supporting clinical research and regulatory decision-making. Integration of COTA's ...

The JASMINE trial showed nipocalimab's efficacy in SLE, meeting primary and secondary endpoints, including steroid sparing ...

So having a representative population is really important. One part of that is being able to enroll more patients in the ...

Explore early data from the ACTS program that reveal the volume and types of patient-reported barriers to cancer care and ...

In today’s ACT Brief, we explore how site initiation can be leveraged to improve early trial performance through demonstrated ...

Securing comparator drugs in the EU is a complex process shaped by availability constraints, regulatory expectations, and competitive market behavior. But if we have the right planning, strong ...